

- **Name:** Fabrice Andre
  - **Current Position & Affiliation:** Head of Research Division, Gustave Roussy Cancer Center (2020-)  
Professor of Medicine, Oncology, Université Paris Saclay (2012-)
  - **Country:** France
- 

- **Educational Background:**

- ◆ Medical School , Université J Fourier, Grenoble, 1990-1996
- ◆ MD degree, Oncology, Université Pierre et Marie Curie, 2000
- ◆ PhD degree, Biotechnology, Université Paris VII, 2002
- ◆ Visiting Assistant Professor, MD Anderson Cancer Center, 2006

- **Professional Experience:**

- ◆ Head, INSERM Unit U981, “Biomarker and new therapeutic targets” (2010-)
- ◆ Chairman, Precision Medicine group, UNICANCER (2014-)
- ◆ Director, National Cancer Precision Medicine Center (PRISM) (2020-)
- ◆ Coordinator, consortium MyProbe (9 M euros) (2018-)
- ◆ Coordinator, consortium CANTO (12 M euros) (2011-)
- ◆ Executive committee member, GENIE consortium (2020-)
- ◆ Editor in Chief, Annals of Oncology (2017-)
- ◆ Founder, Pegascy
- ◆ Member of the ASCO Annual Meeting Education Committee, Breast Cancer (2020-)

- **Professional Organizations:**

- ◆ Scientific committee member, ESMO/ECCO Meeting (2004, 2006, 2008, 2014, 2016, 2017, 2019, 2020, 2021)
- ◆ ASCO Grant selection committee member, 2011-2013
- ◆ IMPAKT, scientific committee chair, 2012
- ◆ Breast International Group, executive committee member, 2014-2018
- ◆ Editor, Breast Cancer section, Annals of Oncology, 2014-2017
- ◆ CRUK Biomarker Expert Review Panel, 2015
- ◆ SABCS Program committee member, 2016-2019
- ◆ CRUK Experimental Medicine Expert Review Panel, 2016-2017
- ◆ CRUK Accelerator Grant Award, 2018-2020
- ◆ CRUK Early Detection Project award 2019

**• Main Scientific Publications:**

1. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, Tursz T, Amigorena S, Raposo G, Angevin E, Zitvogel L. Malignant effusions and immunogenic tumour-derived exosomes. *Lancet*. 2002; 360: 295- 305
2. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R, Delalogue S, Spielmann M. Breast cancer with synchronous metastases: trends in survival during a 14-year period. *J Clin Oncol*. 2004 Aug 15; 22(16): 3302-8.
3. André F, Michiels S, Dessen P, Scott V, Suci V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delalogue S. Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. *Lancet Oncol*. 2009; 10: 381-90
4. Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahnoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. *J Clin Oncol*. 2010 Dec 1; 28(34): 5110-5.
5. Andre F, Delalogue S, Soria JC. Biology-driven phase II trials: what is the optimal model for molecular selection? *J Clin Oncol*. 2011 Apr 1; 29(10): 1236-8.
6. Pusztai L, Hatzis C, Andre F. Reproducibility of research and preclinical validation: problems and solutions. *Nat Rev Clin Oncol*. 2013 Dec; 10(12): 720-4.
7. André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, Lacroix-Triki M, Lacroix L, Cohen P, Gentien D, Adélaïde J, Dalenc F, Goncalves A, Levy C, Ferrero JM, Bonnetterre J, Lefeuvre C, Jimenez M, Filleron T, Bonnefoi H. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). *Lancet Oncol*. 2014; 15: 267-74
8. André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Oncol*. 2014; 15: 580-91
9. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tuting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delalogue S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M,

- Engblom C, Pfirschke C, Prévaille X, Uzè G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, André F\* (equal contribution), Kroemer G\*, Zitvogel L\*. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. *Nat Med.* 2014 Nov; 20(11): 1301-9.
10. Andre F, Arnedos M, Goubar A, Ghouadni A, Delaloge S. Ki67--no evidence for its use in node-positive breast cancer. *Nat Rev Clin Oncol.* 2015 May; 12(5): 296-301.
  11. Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H, Andre F. Precision medicine for metastatic breast cancer--limitations and solutions. *Nat Rev Clin Oncol.* 2015 Dec; 12(12): 693-704.
  12. André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2- Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis from BOLERO-1 and BOLERO-3. *J Clin Oncol.* 2016; 34: 2115-24
  13. Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel- Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F (corresponding author), Soria JC. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. *Cancer Discov.* 2017 Jun; 7(6): 586-595.
  14. Turner NC, Neven P, Loibl S, Andre F. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. *Lancet.* 2017 Jun 17; 389(10087): 2403-2414.
  15. André F. Developing Anticancer Drugs in Orphan Molecular Entities - A Paradigm under Construction. *N Engl J Med.* 2018 Feb 22; 378(8): 763-765.
  16. Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F; International Breast Cancer Study Group and the Breast International Group. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. *Lancet Oncol.* 2019 Mar; 20(3): 371-382.
  17. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Papai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. *N Engl J Med.* 2019 May 16; 380(20): 1929-1940.
  18. Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC,

- Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F. Genomic characterization of metastatic breast cancers. *Nature*. 2019 May; 569(7757): 560-564.
19. Andre F, Ismaila N, Henry NL, Somerfield MR, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Van Poznak C, Wolff AC, Stearns V. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. *J Clin Oncol*. 2019 Aug 1; 37(22): 1956-1964.
20. Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SR, Chan A, Goel S, Catron K, Chapman SC, Price GL, Yang Z, Gainford MC, André F. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarchER): a randomised, open-label, phase 2 trial. *Lancet Oncol*. 2020 Jun; 21(6): 763-775.